However, the inhibition of the function of receptor CB2 in combination with other risk factors (e.g., the impairment of glutamatergic transmission by the use of NMDA receptor antagonist—MK-801) may provoke or potentiate the symptoms of schizophrenia, perhaps in the people predisposed to schizophrenia. The gene discussed is CNR2; the disease is schizophrenia.